Frontlight ResearchEarly access
Active, not recruitingPhase 2
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Key facts
- Who runs it
- Altimmune, Inc.
- Where
- Atlanta, Bastrop, Bradenton, Brownsville, Dallas, Doral, Edinburg, Fort Myers, Fresno, Houston, Indianapolis, La Jolla, Las Vegas, Louisville, Manhasset, Marrero, Miami, Miami Lakes, Naples, New York, North Little Rock, Orlando, Pasadena, Peoria, San Antonio, Seattle, St Louis, Syracuse, Tucson, Waco, West Monroe, Westlake, and Wilmington, United StatesSee the 33 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 121 people enrolled
- Started
- 16 Jun 2025
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pemvidutide
- Placebo
- Record updated
- 17 August 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Male or female ages 18 to 75 years, inclusive
- Overweight or obesity, defined as BMI ≥ 25 kg/m2
- History of alcohol misuse for the prior 3 years, with an alcohol intake ≥ 50 grams per day for males and ≥ 40 grams per day for females on average in the past year
- Evidence of recent alcohol use, defined as PEth level ≥ 35 ng/mL at screening
- Liver stiffness of 10.0-24.9 kPa by VCTE, inclusive
Who cannot take part
- Presence of clinically significant alcohol withdrawal symptoms, defined as CIWA-Ar score ≥ 10 at screening and/or prior to randomization
- History and/or current diagnosis of schizophrenia, bipolar disorder, psychotic disorder, or another severe psychiatric disorder, unless documented as well-controlled by the Investigator for at least 6 months prior to screening and cleared by the Medical Monitor
- History of hospitalization for alcohol withdrawal within the past year
- History of seizures related to alcohol within the past year
- Attempted suicide and/or serious suicidal intention or plan in the past 10 years
Where in United States
Also in 1 other country, 1 site
- Atlanta, GeorgiaHospital not named in the registry
- Bastrop, LouisianaHospital not named in the registry
- Bradenton, FloridaHospital not named in the registry
- Brownsville, TexasHospital not named in the registry
- Dallas, TexasHospital not named in the registry
- Doral, FloridaHospital not named in the registry
- Edinburg, TexasHospital not named in the registry
- Fort Myers, FloridaHospital not named in the registry
- Fresno, CaliforniaHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Indianapolis, IndianaHospital not named in the registry
- La Jolla, CaliforniaHospital not named in the registry
- Las Vegas, NevadaHospital not named in the registry
- Louisville, KentuckyHospital not named in the registry
- Manhasset, New YorkHospital not named in the registry
- Marrero, LouisianaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Miami Lakes, FloridaHospital not named in the registry
- Naples, FloridaHospital not named in the registry
- New YorkHospital not named in the registry
- North Little Rock, ArkansasHospital not named in the registry
- Orlando, FloridaHospital not named in the registry
- Pasadena, CaliforniaHospital not named in the registry
- Peoria, ArizonaHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- Seattle, WashingtonHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
- Syracuse, New YorkHospital not named in the registry
- Tucson, ArizonaHospital not named in the registry
- Waco, TexasHospital not named in the registry
- West Monroe, LouisianaHospital not named in the registry
- Westlake, OhioHospital not named in the registry
- Wilmington, North CarolinaHospital not named in the registry
About the trial
What the trial wants to find out
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.
The 2 groups in the trial
- Pemvidutide 2.4 mgExisting treatment, for comparison
Treatment: Pemvidutide
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
- Record updated
- 17 August 2026